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ABSTRACT
The aims of this study were to detect BRO
b-lactamase types and to evaluate any correlation
with the susceptibility patterns of 90 clinical
isolates of Moraxella catarrhalis. The overall prev-
alences of the bro-1 and bro-2 genes were 78% and
12%, respectively. Penicillin G MICs for BRO-1+
isolates were signiﬁcantly higher than those for
BRO-2+ isolates. All the isolates were susceptible
to amoxycillin–clavulanate, levoﬂoxacin and
ceﬁxime. Resistance to clarithromycin, tetra-
cycline and trimethoprim–sulphamethoxazole
was 1.1%, 2.2% and 1.1%, respectively. One-step,
length-based PCR was an efﬁcient method to
screen for BRO b-lactamase genes.
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Moraxella catarrhalis has been recognised as an
increasingly important human pathogen during
the last 25 years. M. catarrhalis can cause upper
and lower respiratory tract infections in adults
and acute otitis media in children. Although
M. catarrhalis strains are generally susceptible to
most antibiotics used for the treatment of respir-
atory infections, they are resistant to penicillin
because of the widespread production of BRO
b-lactamases [1]. Production of b-lactamase can be
detected using nitroceﬁn disks and isoelectric-
focusing patterns, or by DNA restriction endo-
nuclease analysis [2–4]. Levy and Walker [5] have
described an easy, one-step, length-based PCR
assay that can be used to distinguish BRO-1
and BRO-2 b-lactamase-producing strains. The
present study aimed to use this assay to identify
the BRO-type b-lactamases produced by clinical
isolates of M. catarrhalis from a Turkish Univer-
sity Hospital and to compare their antibiotic
susceptibility patterns.
Ninety M. catarrhalis isolates from different
patients with upper and lower respiratory tract
infections were investigated. The isolates were
identiﬁedusing theCrystal IDSystem forNeisseria–
Haemophilus (Becton Dickinson, Franklin Lakes,
MD, USA). Identiﬁcation was conﬁrmed by
growth at room temperature, hydrolysis of
tributyrin and positive DNase tests [6]. BRO-
negative, BRO-1+ and BRO-2+ control strains
for PCR assays were kindly provided by East
Tennessee State University (Johnson City, TN,
USA) [5]. All of the isolates were stored at )70C
until required.
Antimicrobial susceptibility testing was per-
formed using Etests (AB Biodisk, Solna, Sweden).
MICs of penicillin G, amoxycillin–clavulanate,
trimethoprim–sulphamethoxazole, clarithromy-
cin, levoﬂoxacin, ceﬁxime and tetracycline were
determined according to the manufacturer’s
instructions. MICs were interpreted according to
CLSI breakpoints [7] for Haemophilus spp., except
those for penicillin G, which were interpreted
according to the breakpoints for Staphylococcus
spp. Staphylococcus aureus ATCC 29213 was used
as a quality control strain for susceptibility tests.
Screening for b-lactamase production was per-
formed using nitroceﬁn disks (Becton-Dickinson)
according to the manufacturer’s recommended
procedure. A colour change from yellow to pink
within 5–60 min was considered to be a positive
reaction. S. aureus ATCC 29213 and Haemophilus
inﬂuenzae ATCC 10211 were used as positive and
negative quality control strains, respectively, for
nitroceﬁn disk assays.
DNA extraction was performed using an EZ-10
Spin Column Genomic DNA Minipreps Kit (Bio-
Basic, East Markham, Ontario, Canada). Primer
sequences used to detect BRO b-lactamase genes
were 5¢-CACCCYGTRGGACAAGC and 5¢-AA-
TGACGGCGTTGCATC, with PCR ampliﬁcation
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comprising 94C for 10 min, followed by 25 cycles
of 94C for 30 s, 55C for 60 s and 72C for 40 s,
with a ﬁnal extension at 72C for 7 min [5]. PCR
products of 235 bp (bro-1) or 214 bp (bro-2) were
distinguished on agarose 2% w ⁄ v gels. All neg-
ative PCRs were repeated. MICs of each antimi-
crobial agent were compared for BRO-1+ and
BRO-2+ isolates using Student’s t-test for inde-
pendent samples.
Overall, 85 (94%) of the isolates were b-lacta-
mase-positive according to the nitroceﬁn disk
assay, and 81 (90%) were positive for a BRO
b-lactamase gene by PCR. One of the ﬁve isolates
that were negative by PCR and the nitroceﬁn
assay was resistant to penicillin (MIC 0.5 mg ⁄L).
The PCR and nitroceﬁn results were consistent
for 86 (96%) of the isolates.
Since the ﬁrst report of b-lactamase-producing
M. catarrhalis isolates in 1977 [8], the frequency of
b-lactamase production has increased worldwide
[1]; currently >90% of M. catarrhalis isolates pro-
duce a b-lactamase [2,3,9,10]. Koseoglu et al. [4]
reported that 96.9% of clinical isolates and 90.6%
of carrier strains produced b-lactamase in Turkey.
In the present study, four penicillin-resistant
isolates failed to yield PCR products, but were
nitroceﬁn-positive, suggesting the presence of a
third BRO enzyme, as postulated by Christensen
et al. [11], although BRO-3 is now considered to be
a membrane-bound precursor molecule rather
than a new type of enzyme [12]. Levy and Walker
[5] concluded that PCR failure is probably caused
by mismatches between primer and target
sequences, rather than the absence of a functional
gene, but this was not investigated further in the
present study.
The overall prevalences of the bro-1 and bro-2
genes in the present study were 78% and 12%,
respectively. Similarly, the majority of b-lacta-
mase-producing isolates in many countries
produce BRO-1 [1–4,9,10]. The MIC ranges and
MIC50 and MIC90 values of each antimicrobial
agent for BRO-1+, BRO-2+ and BRO– isolates are
shown in Table 1. Penicillin MICs for BRO-1+
isolates were signiﬁcantly higher than those for
BRO-2+ isolates (t = 3.06, p <0.001; mean ± SD:
BRO-1+ = 5.89 ± 5.06, BRO-2+ = 1.18 ± 0.82). The
MIC90 value of penicillin G for BRO-1
+ isolates
was 16 mg ⁄L, compared with 2 mg ⁄L for BRO-2+
isolates. One of ﬁve BRO– isolates was resistant to
penicillin, suggesting the existence of a different
resistance mechanism. It has been reported that
8% of b-lactamase-negative M. catarrhalis isolates
in Europe are resistant to penicillin, but the
mechanism of resistance remains unknown [13].
Two (2.9%) BRO-1+ isolates, which were also
positive according to the nitroceﬁn disk assay,
were susceptible to penicillin (MIC 0.03 mg ⁄L);
however, it is known that BRO b-lactamases are
relatively weak enzymes that may result in only
low MICs [1].
In the present study, all of the isolates were
susceptible to amoxycillin–clavulanate, levoﬂoxa-
cin and ceﬁxime. One (1.1%) BRO-1+ isolate was
found to be intermediately susceptible to clarith-
romycin, one (1.1%) BRO-1+ isolate was resistant
to trimethoprim–sulphamethoxazole, and two
(2.2%) BRO-1+ isolates were resistant to tetra-
cycline. However, there were no signiﬁcant
differences among the MICs of antimicrobial
agents for BRO-1+ and BRO-2+ isolates, except
for penicillin G. Although M. catarrhalis isolates
are known to be highly susceptible to macro-
lides, tetracycline, ﬂuoroquinolones, second- and
third-generation cephalosporins and b-lactam ⁄
b-lactamase inhibitor combinations, resistance to
erythromycin [14], tetracycline [15] and cipro-
ﬂoxacin [16] has been reported occasionally.
Table 1. MIC range, MIC50 and MIC90 values (mg ⁄L) of seven antimicrobial agents forMoraxella catarrhalis clinical isolates,
grouped according to their BRO b-lactamase type
Antimicrobial agent
BRO-1+ (n = 70) BRO-2+ (n = 11) BRO– (n = 9)
MIC range MIC50 MIC90 MIC range MIC50 MIC90 MIC range MIC50 MIC90
Penicillin G 0.125–16 4 16 0.25–2 1 2 0.03–1 0.125 0.5
AMC ⁄CL <0.01–1 0.06 0.125 <0.01–0.125 0.06 0.06 <0.01–0.06 0.01 0.06
TMP ⁄ SMX 0.008–4 0.06 0.25 <0.002–0.125 0.125 0.25 <0.002–0.125 0.06 0.125
Clarithromycin <0.01–16 0.03 0.06 <0.01–0.06 0.06 0.06 <0.01–0.06 0.06 0.06
Levoﬂoxacin 0.008–0.25 0.03 0.06 <0.02–0.06 0.03 0.06 0.002–0.06 0.03 0.03
Ceﬁxime <0.01–1 0.06 0.25 <0.01–0.125 0.06 0.125 <0.01–0.25 0.03 0.125
Tetracycline 0.03–16 0.125 0.25 <0.01–0.25 0.125 0.125 0.06–0.25 0.125 0.25
AMC ⁄CL, amoxycillin–clavulanate; TMP ⁄ SMX, trimethoprim–sulphamethoxazole.
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Resistance to the trimethoprim–sulphameth-
oxazole combination is also now being reported
with greater frequency [10,13].
In conclusion, the increasing rates of resistance
to several antibiotics among M. catarrhalis isolates
make continuous monitoring of resistance pat-
terns important. Although the nitroceﬁn disk
assay is adequate for routine testing to detect
the production of b-lactamase, it is important to
distinguish the BRO b-lactamases in order to
predict susceptibility patterns and to monitor
long-term trends in susceptibility among
M. catarrhalis strains. The one-step, length-based
PCR assay seems to be an easy and efﬁcient
method for distinguishing the BRO b-lactamases.
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